Search
Ganaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigational[A245995] Ganaxolone, similar to its endogenous counterparts, is a positive allosteric modulator of GABA<sub>A</sub> receptors. … Ganaxolone is the 3β-methylated synthetic analog of [allopregnanolone],[L41130] a metabolite of [progesterone].[A3197] Ganaxolone belongs to a class of compounds referred to as neurosteroids.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesAX200
go.drugbank.com/drugs/DB05093InvestigationalAX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. The expression of the endogenous AX200 protein in the brain is increased af...
Leptin
go.drugbank.com/drugs/DB05098InvestigationalAlthough leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. … These people are said to be resistant to the effects of leptin, in much the same way that people with type 2 diabetes are resistant to the effects of insulin.
Ancrod
go.drugbank.com/drugs/DB05099ApprovedWithdrawnCurrently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S. … FDA granted a 'fast-track status' for investigation of ancrod use in patients suffering from acute ischemic stroke, a life threatening condition caused by the blockage of blood vessels supplying blood
Categories: Venombin APrinomastat
go.drugbank.com/drugs/DB05100InvestigationalAs a lipophilic agent, prinomastat crosses the blood-brain barrier. … Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and
Rupintrivir
go.drugbank.com/drugs/DB05102ExperimentalRupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV) infections. … Rupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells. It is designed to combat colds caused by rhinovirus.
Categories: Heterocyclic Compounds, 1-RingIR208
go.drugbank.com/drugs/DB05106InvestigationalIR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation. … It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.
16-Bromoepiandrosterone
go.drugbank.com/drugs/DB05107Investigational16-Bromoepiandrosterone is an injectable formulation of a compound called alpha-epi-bromide. … It is a chemical relative of DHEA which was selected for development after it showed antiretroviral activity in laboratory tests.
Trabectedin
go.drugbank.com/drugs/DB05109ApprovedInvestigationalTrabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. … Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically.
Categories: Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexProducts: Yolisar 1 mg I.V. İnfüzyonluk Çözelti Hazırlamada Kullanılacak Konsantre İçin Toz, 1 ADET, YONDELIS® 1MG POLVO LIOFILIZADO PARA INYECCIÓNVIR201
go.drugbank.com/drugs/DB05110Experimentalis an experimental therapeutic vaccine currently in clinical trial. The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.